DBNDD2 (dysbindin domain containing 2) is a regulatory protein that modulates casein kinase-1 (CK1) activity through inhibition of CSNK1D autophosphorylation in vitro, suggesting a role in negative regulation of protein kinase signaling. The protein functions as a CK1 binding protein (CK1BP) that reduces α-synuclein oligomerization and aggregation independent of serine 129 phosphorylation 1, with potential implications for neurodegenerative diseases. DBNDD2 expression is regulated by miR-574-3p and is involved in neurometabolic and chr20 neuronal injury response pathways, including brain responses to stroke 2. In cancer biology, DBNDD2 has been identified as a component of long non-coding RNA competing endogenous RNA networks in cervical cancer, where the SYS1-DBNDD2 lncRNA shows diagnostic value when combined with other biomarkers 3. The gene functions primarily in signal transduction regulation and protein-protein interactions, with emerging clinical significance in both neurodegenerative diseases and cancer diagnostics. Its role as a CK1 inhibitor positions DBNDD2 as a potential therapeutic target for α-synucleinopathies and related protein aggregation disorders.